6. (For Cohort A) Measurable disease per RECIST. (For cohort B) Clinical or radiologic primary tumor size of at least 1.5cm prior to enrollment onto protocol 2014-0185 (ARTEMIS). Primary tumor of at least 1.0 cm or evidence of continued lymphnode involvement by imaging (ultrasound or MRI) after Adriamycin-based neoadjuvant therapy.